Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus Sorafenib vs Sorafenib in 3rd-line mRCC
NCT02330783Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Dec 2014
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in metastatic renal cell carcinoma (mRCC), sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02330783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02330783.